This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Gastrointestinal Tolerability Study Of Dimethyl Fu...
Clinical trial

Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (TOLERATE)

Read time: 1 mins
Last updated:25th Apr 2014

The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by subjects with relapsing-remitting multiple sclerosis initiating therapy with BG00012 (dimethyl fumarate, DMF) in the clinical practice setting.

The secondary objectives of this study in this study population are as follows: To evaluate gastrointestinal-related events requiring symptomatic therapy and the role of those therapies over time; To evaluate gastrointestinal-related events that lead to a physician's decision to manage the events with BG00012 dose modification; and To evaluate gastrointestinal-related events that lead to BG00012 discontinuation after the use of symptomatic therapy.

Category Value
Study start date 2014-04-25

View full details